

# Partnering in Immunology & Inflammation



Our goal is to discover and develop breakthroughs in animal health for diseases with significant unmet need. To achieve this, we're investing in cutting-edge science and technology to expand and accelerate our drug discovery for the next generation of treatments and preventive therapies. With a track record of converting research and development innovation into blockbuster products, our robust immunology & inflammation pipeline builds on this legacy with an ambition to deliver innovative solutions in diseases with high unmet need such as osteoarthritis and chronic kidney disease.

Collaborations with innovative and entrepreneurial partners are helping solve the biggest challenges in animal health. We believe that by working together we can bring critical diversity to innovation and accelerate the next wave of therapeutics that will transform the health and well-being of animals now and in generations to come.

## Partnering Interests

Actively pursuing new partnerships in our research focus areas and open to a variety of partnership models to explore:

- Canine atopic dermatitis
- Inflammatory bowel disease
- Osteoarthritis
- Chronic kidney disease

## Research Focus

- Key processes in the development of immune disorders and inflammatory diseases
- Disease mechanisms and common pathways to create synergies across research programs

SCAN ME



## Collaboration Driving Innovation

- Growing our global community of innovation partners
- Multiple collaborations advancing new therapies
- Long-term partnerships for the next generation of breakthroughs

## Investing in Animal Health Innovation



**450+ million EUR**

R&D for new medicines



**Global**

R&D presence in Europe, N. America, Asia



**~1,200**

staff in R&D facilities worldwide



**>250**

innovation collaborations

## Some of our Partners



## Meet the Team



**Hervé Poulet**

[hervé.poulet@boehringer-ingelheim.com](mailto:hervé.poulet@boehringer-ingelheim.com)

